
    
      This is a Phase II double-blind, randomized, dose-comparison, multicenter study in the United
      States of three different dose levels of MEDI-517 (HPV-16/18 VLP AS04 vaccine) and one dose
      of MEDI-517 formulated with aluminum hydroxide, with doses administered at 0, 30 and 180
      days. Healthy female volunteers 18 through 30 years of age will be entered into 4 treatment
      arms. The objectives of study are to evaluate reactogenicity, safety and immunogenicity.
    
  